# First in Patient Study for PF-06840003 in Malignant Gliomas

> **NCT02764151** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 17 (actual)

## Conditions studied

- Oligodendroglioma
- Astrocytoma
- Malignant Glioma

## Interventions

- **DRUG:** PF-06840003

## Key facts

- **NCT ID:** NCT02764151
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-09-09
- **Primary completion:** 2018-12-26
- **Final completion:** 2018-12-26
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Sponsor decided to prematurely terminate the study and not to pursue marketing approval for the indication of malignant glioma.
- **Last updated:** 2020-01-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02764151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02764151, "First in Patient Study for PF-06840003 in Malignant Gliomas". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02764151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*